Perennial Allergic Rhinitis Clinical Trial
Official title:
A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis
Verified date | February 2010 |
Source | CJ HealthCare Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Institutional Review Board |
Study type | Interventional |
Title of Study:
A randomized, parallel, double-blind, multi-center, comparative study to evaluate the
efficacy and safety of Cosalin monotherapy versus Cosalin and Xarlin combination therapy in
patients with allergic rhinitis
Objective of study:
To exploratively evaluate superiority of combination therapy - twice-daily Cosalin Tab
(Petasites hybridus CO2 extract) with once-daily Xarlin Tab (Levocetirizine HCl) - compared
to monotherapy of Cosalin with allergic rhinitis subjects.
Status | Enrolling by invitation |
Enrollment | 100 |
Est. completion date | |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 66 Years |
Eligibility |
Inclusion Criteria: 1. Male and female volunteer more than 18 years old and less than 66 years old. 2. A volunteer who is informed about this study and sign the informed consent. 3. A volunteer who is diagnosed perennial allergic rhinitis greater than grade3 at visit 1(screening visit) by allergy skin test or serum IgE antibody assay in 24 months. 4. A volunteer who has score 8 and more than 8 point 4 Total Symptom Score (4TSS - runny nose, nasal congestion, itchy nose, sneezing). Exclusion Criteria: 1. A volunteer who has hypersensitivity to Levocetirizine or Hydroxyzine 2. A volunteer who has hypersensitivity to Petasites hybridus leaves. 3. A volunteer who has anaphylaxis or hypersensitivity to allergy skin test. 4. A volunteer who has serious renal failure or liver failure. Ingestion of antibiotics during previous two weeks from Visit 1, cause of upper respiratory infection(include paranasal sinus). 5. A volunteer who need to use steroids cause of asthma. 6. A volunteer who is using steroids, decongestants, antihistamine. 7. A volunteer who has rhinitis medicamentosa. 8. A volunteer who has seasonal allergic rhinitis. 9. A volunteer who has Galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption genetic disorder . 10. A volunteer who is an alcoholic or a drug addict. 11. Women who are pregnant, breast-feeding, women who plan to get pregnant during the trial period, or do not use authorized contraceptive methods (e.g: sterilization, intrauterine device, combined use of oral contraceptives and barrier contraceptive, combined use of other hormone delivery systems and barrier contraceptive and combined use of contraceptive cream, jelly or foam and diaphragm or condom) in spite of possibility of pregnancy. 12. A volunteer who has experience to take test products in 1 month. 13. A volunteer who is concluded poor compliance or fail to follow medical instruction |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CJ HealthCare Corporation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare efficacy improvement of combination therapy group and mono therapy group by percent change of 4 TSS from baseline to end of treatment by investigator. | 2 weeks | No | |
Secondary | Compare percent change of evening reflective 4 TSS from baseline to end of treatment by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of instantaneous 4 TSS from baseline to end of treatment by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of evening reflective nasal congestion score from baseline to end of treatment by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of instantaneous nasal congestion score from baseline to end of treatment by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of evening reflective 5 TSS (5 TSS - runny nose, itchy nose, sneezing, ocular symptom, nasal congestion)by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of instantaneous 5 TSS by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of evening reflective 4 TSS from baseline to each day by using patient diary. | 2 weeks | No | |
Secondary | Compare percent change of instantaneous 4 TSS from baseline to each day by using patient diary. | 2 weeks | No | |
Secondary | Compare improvement of QoL from baseline to end of treatment, by using RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire). | 2 weeks | No | |
Secondary | Compare responder rate (> 50% evening reflective 4TSS improvement) by using patient's diary. | 2 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01654536 -
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
|
Phase 4 | |
Completed |
NCT01539304 -
Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT01221285 -
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
|
Phase 1 | |
Terminated |
NCT00491374 -
Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)
|
Phase 4 | |
Completed |
NCT00783224 -
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
|
Phase 3 | |
Completed |
NCT04324918 -
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT02532179 -
Subcutaneous Immunotherapy for Mouse in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01451541 -
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
|
Phase 3 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT01549340 -
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
|
N/A | |
Completed |
NCT01018862 -
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00789555 -
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00261287 -
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
|
Phase 3 | |
Completed |
NCT00974571 -
Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
|
Phase 3 | |
Completed |
NCT04654702 -
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
|
||
Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
Completed |
NCT01380327 -
Biomarkers of Cockroach Sublingual Immunotherapy 2
|
Phase 1/Phase 2 | |
Completed |
NCT01116778 -
the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00359216 -
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
|
Phase 4 | |
Completed |
NCT00163514 -
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
|
Phase 3 |